Ocean Biomedical, Inc.

Equities

OCEA

US67644C1045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 08:05:03 07/06/2024 pm IST			5-day change	1st Jan Change
1.455 ^USD	0.00%		-3.37%	+115.23%

30/05	Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down	MT
15/04	Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Ocean Biomedical, Inc. announced that it expects to receive $10 million in funding from Poseidon Bio, LLC

October 04, 2023

Ocean Biomedical, Inc. announced a private placement of unsecured convertible debt for the gross proceeds of up to $10 million on October 4, 2023. The transaction will include participation from returning investors, Poseidon Bio, LLC. The conversion price will be $10.34 per share, subject to certain potential adjustments.

The notes will mature in one year following the issuance date. The promissory notes may be issued in one or more closings.

Latest news about Ocean Biomedical, Inc.

Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down	30/05	MT
Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/04	CI
Ocean Biomedical, Inc. Appoints Amy Griffith as Director	09/03	CI
Ocean Biomedical, Inc. Announces CFO Changes	05/03	CI
North American Morning Briefing : S&P 500 Futures -2-	23/02	DJ
North American Morning Briefing : Central Bankers -2-	17/01	DJ
North American Morning Briefing : Stocks to -2-	10/01	DJ
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited	03/01	DJ
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	20/12	DJ
North American Morning Briefing : Traders Await -2-	13/12	DJ
Ocean Biomedical Announces Publication of Breast Cancer Research Uncovering New Tumor Suppression Pathway for its Proprietary Anti-Chi3L1 Antibody	05/12	CI
Ocean Biomedical Receives Non-Compliance Notice From Nasdaq	30/11	MT
North American Morning Briefing : Stock Futures -2-	29/11	DJ
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading	22/11	DJ
Ocean Biomedical Says Potential Treatment for Advanced Solid Tumors Yields 'Highly Compelling' Preclinical Data	14/11	MT
Ocean Biomedical, Inc. Announces Positive Preclinical Oncology Data for Vron 0300, Presented At Sitc 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics	14/11	CI
Virion Therapeutics and Joint Venture Partner, Ocean Biomedical Announces First Patients Dosed with Novel Immunotherapy Evaluating A Functional Cure for Chronic Hepatitis B Virus Infection	26/23/26	CI
Ocean Biomedical, Inc. Announces Resignation of Jerome Ringo as Member of Board of Directors	13/23/13	CI
Ocean Biomedical, Virion Therapeutics Form Joint Venture to Seek Cures for Cancer, Infectious Diseases	12/23/12	MT
Ocean Biomedical, Inc. announced that it expects to receive $10 million in funding from Poseidon Bio, LLC	04/23/04	CI
Ocean Biomedical Says Data Show Antibody Candidate Can Restore Treatment Sensitivity to AstraZeneca's Lung Cancer Drug	03/23/03	MT
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to Astrazeneca?s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers	03/23/03	CI
Ocean Biomedical Secures US Patent for Anti-Chitinase 1 Small Molecule Candidate	29/23/29	MT
Ocean Biomedical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Ocean Biomedical, Inc. Provides Latest Updates on Its Broad Programs in Malaria, Fibrosis, and Multiple Cancers	10/23/10	CI

Chart Ocean Biomedical, Inc.

Duration

Period

More charts

Company Profile

Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
OCEAN BIOMEDICAL, INC.	+115.23%	5.04Cr
VERTEX PHARMACEUTICALS INCORPORATED	+18.85%	13TCr
REGENERON PHARMACEUTICALS, INC.	+13.73%	11TCr
BIONTECH SE	-4.54%	2.46TCr
ARGENX SE	+3.29%	2.28TCr
GENMAB A/S	-10.79%	1.82TCr
WUXI APPTEC CO., LTD.	-41.48%	1.65TCr
BEIGENE, LTD.	-12.18%	1.65TCr
NEUROCRINE BIOSCIENCES, INC.	+2.49%	1.34TCr
SAREPTA THERAPEUTICS, INC.	+24.59%	1.11TCr

Bio Therapeutic Drugs